Recursion claims that its artificial-intelligence-backed drug discovery platform gets smarter each time it pinpoints a new drug candidate—which is why, even with several of those candidates already | Recursion claims that its AI platform gets smarter each time it pinpoints a new drug candidate—which is why, even with several candidates already in clinical trials, the company is still making moves to strengthen its tech.
